FRANK MCCORMICK - 29 Oct 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Will Solis, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
29 Oct 2025
Net transactions value
-$13,206,528
Form type
4
Filing time
31 Oct 2025, 16:38:45 UTC
Previous filing
29 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MCCORMICK FRANK Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 31 Oct 2025 0001257809

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Sale $7,317,315 -111,755 -13% $65.48 766,583 29 Oct 2025 By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 F1, F2
transaction BBIO Common Stock Sale $2,059,749 -31,116 -4.1% $66.20 735,467 29 Oct 2025 By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 F1, F3
transaction BBIO Common Stock Sale $236,130 -3,497 -0.48% $67.52 731,970 29 Oct 2025 By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 F1, F4
transaction BBIO Common Stock Sale $588,985 -8,598 -1.2% $68.50 723,372 29 Oct 2025 By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 F1, F5
transaction BBIO Common Stock Sale $3,004,349 -43,393 -6% $69.24 679,979 29 Oct 2025 By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 F1, F6
holding BBIO Common Stock 83,275 29 Oct 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.
F2 Represents the weighted average sale price of the shares sold from $65.00 to $65.999 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3 Represents the weighted average sale price of the shares sold from $66.00 to $66.9875 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4 Represents the weighted average sale price of the shares sold from $67.00 to $67.996 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5 Represents the weighted average sale price of the shares sold from $68.005 to $68.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F6 Represents the weighted average sale price of the shares sold from $69.00 to $69.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.